Benzinga | Jul 15, 2020 09:20AM EDT

Morgan Stanley Maintains Overweight on Acceleron Pharma, Raises Price Target to $123

Morgan Stanley maintains Acceleron Pharma (NASDAQ:XLRN) with a Overweight and raises the price target from $122 to $123.